Ibogaine
Ibogaine Treatment
A comprehensive, evidence-led resource on ibogaine: pharmacology, the research base, cardiac risk, candidacy, preparation and integration.
Evaluating providers
Standards in this field vary enormously, and the marketing does not distinguish them. These are the questions worth asking any provider — including us. Nothing here is a rating of specific facilities; it is a framework for making an informed decision.
Why this matters
Reviews of ibogaine-associated fatalities repeatedly identify the same context: pre-existing cardiac disease that was not detected, interacting medication that was not reviewed, concurrent substance use, and administration without medical monitoring or the means to respond to an arrhythmia. The compound's risk profile is real, and the setting substantially determines whether that risk is managed or simply accepted.
This is why choosing a provider is not a matter of comfort, cost or atmosphere. The questions below are about whether identifiable risks are being looked for and whether there is a plan if something goes wrong.
We operate a private facility, so we are not a neutral party. That is exactly why this page names criteria rather than facilities, and why we would rather you use it to interrogate us than accept a claim. If a question here produces an unsatisfactory answer from any provider, that is useful information.
Read the safety considerations and speak to your own physician. Do not discontinue prescribed medication in order to qualify for treatment anywhere.
Checklist
Ask whether a baseline ECG with QTc measurement is mandatory before administration, who reads it, and what findings result in decline. A provider that cannot describe its exclusion criteria does not have any.
Ask what happens if an arrhythmia occurs: what monitoring is in place, what equipment and medication are on site, who is trained to use them, and how far away the nearest hospital with cardiac capability is.
Ask which licensed clinicians are physically present during administration and for the hours afterwards, what their credentials are, and whether that presence is continuous or intermittent.
Ask what is monitored, at what intervals, and for how long after administration. Cardiac monitoring that stops when the acute phase ends does not match the pharmacology of a long-lived metabolite.
Ask to see the screening protocol and the consent document before you travel. Consent that names serious adverse events and the possibility of death is a sign of seriousness, not a warning sign.
Ask directly what the evidence base is. An accurate answer includes that no completed randomized controlled trials exist and that outcomes vary. Any provider claiming a cure, a guaranteed result, a perfect safety record or a brain reset is telling you something the literature does not support.
Ask how prescribed medication is reviewed, who liaises with your existing prescriber, and how interacting drugs are managed. A provider that tells you to stop your medication before arriving on your own is a serious concern.
Ask how often people are declined. A provider that accepts effectively everyone who can pay is not screening, whatever it calls the process.
Ask what happens after discharge — whether continuing care is arranged, whether there is any follow-up contact, and whether outcomes are tracked at all.
Ask under what legal framework and licensing the facility operates in its jurisdiction. Ibogaine's legal status varies by country and it is not approved for treatment in the United States.
Ask what is and is not included, in writing, including the cost consequences of being declined at screening or of a longer stay.
The most informative signal is often the response to this list. Discomfort at being asked about emergency equipment is itself an answer.
References
Explore
Related
Ibogaine
A comprehensive, evidence-led resource on ibogaine: pharmacology, the research base, cardiac risk, candidacy, preparation and integration.
Ibogaine
A consumer guide to evaluating an ibogaine provider: screening, cardiac assessment, medical oversight, emergency preparedness and transparency.
Ibogaine
QT prolongation, arrhythmia risk, CYP2D6 metabolism, drug interactions and electrolytes — what the safety literature establishes and what remains uncertain.
Ibogaine
Why the weeks after an experience matter: reflection, behavior, sleep, nutrition, relationships, meaning and ongoing professional support.
Insights
Benzodiazepine Treatment
Benzo detox and withdrawal treatment: a physician-directed taper, twenty-four hour monitoring, nine hours of daily therapy and the in-house Brain Repair IV protocol.
Ibogaine
A consumer guide to evaluating an ibogaine provider: screening, cardiac assessment, medical oversight, emergency preparedness and transparency.
Benzodiazepine Treatment
Physician-supervised benzodiazepine detox and withdrawal support: gradual tapering, nine hours of daily one-to-one therapy, the in-house Brain Repair IV protocol, and whole-body restoration in a private oceanfront setting.
Mental Health
An integrative approach to PTSD, trauma, depression and anxiety that treats sleep, nutrition, environment and behavior as clinical variables.
Holistic Treatment
Rehabilitation as system repair: mental health, behavior, environment, nutrition and sleep, with specialized medical support where it is needed.
Ibogaine
Why the weeks after an experience matter: reflection, behavior, sleep, nutrition, relationships, meaning and ongoing professional support.
Ibogaine
Medical, psychological and practical preparation: history, medication review, ECG, laboratory assessment, consent and integration planning.
Ibogaine
QT prolongation, arrhythmia risk, CYP2D6 metabolism, drug interactions and electrolytes — what the safety literature establishes and what remains uncertain.
Admissions is a confidential clinical conversation, not a sales call. We review history, current medication, and goals before anyone is accepted.